FGFR2 overexpression	Gastric Cancer	FGFR2 overexpression	Gastric Cancer	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2	AMG 552 Sensitive: C2 – Inclusion Criteria AMG 552 Sensitive : C2
FGFR2 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR2 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR2 overexpression	Breast Cancer	FGFR2 overexpression	Breast Cancer	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
FGFR2 overexpression	Hormone Receptor Positive Breast Cancer	FGFR2 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3	palbociclib + BAY 1163877 Sensitive: C3 – Early Trials palbociclib + BAY 1163877 Sensitive : C3
FGFR2 overexpression	Gastrointestinal Cancer	FGFR2 overexpression	Gastrointestinal Cancer	ARQ 087 Sensitive: D – Preclinical ARQ 087 Sensitive : D	ARQ 087 Sensitive: D – Preclinical ARQ 087 Sensitive : D
FGFR2 overexpression	Breast Cancer	FGFR2 overexpression	Breast Cancer	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D	ponatinib Sensitive: D – Preclinical ponatinib Sensitive : D
FGFR2 overexpression	Breast Cancer	FGFR2 overexpression	Breast Cancer	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D
FGFR2 overexpression	Cholangiocarcinoma	FGFR2 overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D

FGFR2 overexpression

Associations